Allergan, Inc. v. Teva Pharmaceuticals USA, Inc. et al, No. 2:15-cv-01455 (E.D. Tex. Jan. 26, 2017)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

B efore the Court is Mylan Pharmaceuticals Inc. , and Mylan Inc.’s Motion to Limit the Number of Asserted Patent Claims , Dkt. No. 238. In reliance on the representations made by plaintiff Allergan, Inc., as to the reductions it will make in the number of it s asserted claims, the Court DENIES the motion. BACKGROUND Allergan initially asserted a total of 157 claims in six patents in this case. After the Court urged Allergan to reduce the number of asserted claims, Allergan lowered the number by about 20 percent to 126 claims.